Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented DCVC Bio in the transaction. DCVC Bio announced the formation of its $400 million fund, DCVC Bio III....
DCVC Bio’s $400 Million Closing of DCVC Bio III
Section 32’s Closing of $525 Million Fund 5
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Section 32 in the transaction. Section 32 announced the closing of its $525 million fifth fund formation, Fund...
Eclipse’s $1.23 Billion Formation of Two Funds
Gunderson Dettmer advised Eclipse on the deal. Eclipse announced the formation of its $720 million Eclipse Fund V and $510 million Eclipse Early Growth Fund II....
Section 32’s $740 Million Fund Formation
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Section 32 on the deal. Section 32 announced the formation of its $740 million fourth fund, Section 32 Fund...
Eclipse Ventures’ $500 Million Fund Closing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Eclipse Ventures on the deal. Eclipse Ventures announced the closing of its fourth fund of $500M. Eclipse backs companies...
Foresite Capital’s Fundraising
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Foresite Capital on the deal. Foresite Capital announced the formation of the fund’s fifth fund, which is comprised of...